

C. DIFFICILE INFECTION (CDI)—

A vicious cycle of recurrence that results in a significant burden^{1,2}

APPROXIMATELY HALF A MILLION CDI CASES
IN THE UNITED STATES ANNUALLY^{2,3}

RECURRENT CDI (rCDI) AFFECTS PATIENT QUALITY OF LIFE
AND HOSPITAL QUALITY METRICS AND REIMBURSEMENT



Mortality: 6%³

Mortality in patients with COVID-19 and CDI: 44%⁴



Sepsis: 27%⁵



Heart failure: 43%⁶



Bowel surgery: 7%⁵



Colectomy: 6%⁵



Re-recurrence: 50%⁷



**Up to 85% of all patients with rCDI
were hospitalized in 12 months⁸**



**37% of patients with rCDI were
hospitalized at least 3 separate times⁹**



**Hospitalizations average 18 days⁶;
Emergency department visits average 4 per year²**



**84% of patients with
rCDI are readmitted⁸**



**-\$3K to -\$29K gap exists in
reimbursement per patient¹⁰**



**\$131K to \$207K comprised total
cost of a patient with rCDI²**

BREAK THE CYCLE



LEARN MORE ABOUT BREAKING THE
CYCLE OF *C. DIFF* RECURRENCE AT
POWEROFMICROBIOME.COM



Antibiotics are the standard of care for the treatment of *C. diff* and effective for some. However, their use has been shown to disrupt the ecology of the gut microbiome and are a predominant risk factor for CDI recurrence.¹¹

References: 1. Centers for Disease Control and Prevention. <https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf>. Accessed June 24, 2020. 2. Feuerstadt P, et al. *J Med Econ*. 2020;23(6):603-609. 3. Lessa FC, et al. *N Engl J Med*. 2015;372(9):825-834. 4. Sandhu A, et al. [published online May 22, 2020]. *Emerg Infect Dis*. 2020;26(9):10.3201/eid2609.202126. doi:10.3201/eid2609.202126. 5. Scott TA, et al. AGA Abstracts. 2020;158(6)(suppl 1):s976. 6. Unni S, et al. Presented at AMCP 2020. April 21-24, 2020; Houston, Texas. 7. Riddle DJ, Dubberke ER. *Infect Dis Clin North Am*. 2009;23(3):727-743. 8. Rodrigues R, et al. *Infect Control Hosp Epidemiol*. 2017;38(2):196-202. 9. Unni S, et al. *JMCP*. 2020;26(4a):s7. 10. Zilberberg MD, et al. *Medicine*. 2018;97(36):e12212. doi:10.1097/MD.00000000000012212. 11. McDonald LC, et al. *Clin Infect Dis*. 2018;66(7):e1-e48.

FERRING
PHARMACEUTICALS